Health Industry Headlines: Innovations, Approvals, and Market Moves

This update highlights pivotal events in the health sector, including FDA approvals for heart devices, RSV vaccine success in Canada, initiatives for mpox vaccine funding in Africa, and bird flu testing expansions. Additionally, it addresses potential impacts of US tariffs on pharma, and innovations in infant formula distribution in the UK.

In a series of significant industry advancements, the U.S. FDA has given its nod to Johnson & Johnson's Varipulse device aimed at treating abnormal heart rhythms, marking a milestone in cardiac care technology. Additionally, Canada's health authorities have cleared Moderna's RSV vaccine for elderly citizens, setting the stage for widespread immunization by 2025.

As the pharmaceutical landscape adjusts to potential U.S. tariffs, Italian firm Recordati remains unfazed, projecting no adverse effects on its operations. Meanwhile, the African health community urges U.S. President-elect Donald Trump to uphold his predecessor's promises for substantial mpox vaccine funding.

The health sector is also witnessing regulatory shifts, with the FDA proposing a ban on phenylephrine in cold medications due to inefficacy and expanding bird flu testing protocols. In the UK, the Competition and Markets Authority suggests reforms in infant formula marketing, aiming for consumer clarity and cost-efficiency.

(With inputs from agencies.)